Drugs / shmiR Lentivirus Vector
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT07640815 | — | sickle cell disease | David Williams | Temporarily not available | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | shmiR Lentivirus Vector | “Expanded Access Protocol for Gene Therapy Utilizing shmiR Lentivirus Vector to Induce Fetal Hemoglobin in Sickle Cell Disease” NCT07640815 ↗ |
| Action | Inhibit | “Decreasing the expression of this gene in sickle cell patients could increase the amount of fetal hemoglobin while simultaneously reducing the amount of sickle hemoglobin in their blood” NCT07640815 ↗ |
| Target | BCL11A | “The gene we are targeting for change in this study that controls the level of fetal hemoglobin is called BCL11A.” NCT07640815 ↗ |